187 related articles for article (PubMed ID: 28173069)
1. A genetic variation associated with plasma erythropoietin and a non-coding transcript of PRKAR1A in sickle cell disease.
Zhang X; Shah BN; Zhang W; Saraf SL; Miasnikova G; Sergueeva A; Ammosova T; Niu X; Nouraie M; Nekhai S; Castro O; Gladwin MT; Prchal JT; Garcia JG; Machado RF; Gordeuk VR
Hum Mol Genet; 2016 Oct; 25(20):4601-4609. PubMed ID: 28173069
[TBL] [Abstract][Full Text] [Related]
2. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
Papassotiriou I; Voskaridou E; Stamoulakatou A; Loukopoulos D
Hematol J; 2000; 1(5):295-300. PubMed ID: 11920206
[TBL] [Abstract][Full Text] [Related]
3. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.
Little JA; McGowan VR; Kato GJ; Partovi KS; Feld JJ; Maric I; Martyr S; Taylor JG; Machado RF; Heller T; Castro O; Gladwin MT
Haematologica; 2006 Aug; 91(8):1076-83. PubMed ID: 16885048
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin levels in patients with sickle cell disease do not correlate with known inducers of erythropoietin.
Pulte ED; McKenzie SE; Caro J; Ballas SK
Hemoglobin; 2014; 38(6):385-9. PubMed ID: 25405915
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
Taylor CM; Kasztan M; Sedaka R; Molina PA; Dunaway LS; Pollock JS; Pollock DM
Am J Physiol Regul Integr Comp Physiol; 2021 May; 320(5):R630-R640. PubMed ID: 33624556
[TBL] [Abstract][Full Text] [Related]
7. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
8. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
9. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.
Gordeuk VR; Campbell A; Rana S; Nouraie M; Niu X; Minniti CP; Sable C; Darbari D; Dham N; Onyekwere O; Ammosova T; Nekhai S; Kato GJ; Gladwin MT; Castro OL
Blood; 2009 Nov; 114(21):4639-44. PubMed ID: 19724057
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.
Aneni EC; Hamer DH; Gill CJ
Trop Med Int Health; 2013 Mar; 18(3):313-27. PubMed ID: 23320577
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F
Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719
[TBL] [Abstract][Full Text] [Related]
13. Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
Lopes FC; Traina F; Almeida CB; Leonardo FC; Franco-Penteado CF; Garrido VT; Colella MP; Soares R; Olalla-Saad ST; Costa FF; Conran N
Haematologica; 2015 Jun; 100(6):730-9. PubMed ID: 25769545
[TBL] [Abstract][Full Text] [Related]
14. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia.
Lemonne N; Charlot K; Waltz X; Ballas SK; Lamarre Y; Lee K; Hierso R; Connes C; Etienne-Julan M; Romana M; Connes P
Haematologica; 2015 Oct; 100(10):e383-6. PubMed ID: 26137960
[No Abstract] [Full Text] [Related]
16. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Almeida CB; Traina F; Lanaro C; Canalli AA; Saad ST; Costa FF; Conran N
Br J Haematol; 2008 Sep; 142(5):836-44. PubMed ID: 18564357
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolism.
Yahouédéhou SCMA; Adorno EV; da Guarda CC; Ndidi US; Carvalho SP; Santiago RP; Aleluia MM; de Oliveira RM; Gonçalves MS
Pharmacogenomics J; 2018 Dec; 18(6):730-739. PubMed ID: 30206297
[TBL] [Abstract][Full Text] [Related]
18. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease.
Canalli AA; Franco-Penteado CF; Traina F; Saad ST; Costa FF; Conran N
Eur J Haematol; 2007 Oct; 79(4):330-7. PubMed ID: 17680813
[TBL] [Abstract][Full Text] [Related]
19. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia.
Kumkhaek C; Taylor JG; Zhu J; Hoppe C; Kato GJ; Rodgers GP
Br J Haematol; 2008 Apr; 141(2):254-9. PubMed ID: 18318767
[TBL] [Abstract][Full Text] [Related]
20. Investigational agents for sickle cell disease.
Okpala I
Expert Opin Investig Drugs; 2006 Aug; 15(8):833-42. PubMed ID: 16859388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]